UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~November~~December 1531, 2010

TIENS BIOTECH GROUP (USA), INC.

(Exact name of registrant as specified in its charter)

Delaware	001-32477	75-2926439
(State or other jurisdiction	(Commission File Number)	(I.R.S. Employer
of incorporation)		Identification Number)

No. 176, ~~Xinyuan~~Yuanquan ~~Rd.~~Road, Wuqing New -Tech Industrial Park, Tianjin, China 301700

(Address of principal executive offices)

Registrant’'s telephone number, including area code: (（86)-）22-8213-~~7914~~7335

~~No. 6, Yuanquan Rd., Wuqing~~Not ~~New Tech Industrial Park, Tianjin, China 301700~~applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting ~~materials~~material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2 5.02 ~~Results~~ Departure of ~~Operations~~Directors or ~~and~~Certain ~~Financial~~Officers; Election of Directors; Appointment of Certain Officers; ~~Condition~~Compensatory Arrangements of Certain Officers.

OnEffective ~~November~~as 15of December 31, 2010, Howard Balloch resigned from his position as Director of Tiens Biotech Group (USA), Inc. (the “Company”). Mr. ~~issued~~Balloch was a ~~press~~member ~~release~~of ~~reporting~~the Audit Committee of the ~~Company’s~~Board ~~financial~~of ~~results~~Directors ~~for~~of the Company. There ~~fiscal~~were ~~quarter ended~~no ~~September~~disagreements ~~30,~~between ~~2010~~Mr. ~~The~~ ~~full~~Balloch ~~text~~and ofthe Company on any matter relating to the ~~press~~Company’s ~~release~~operations, ispolicies ~~set~~or ~~forth~~practices, inwhich ~~Exhibit~~resulted ~~99.1~~in ~~attached~~his ~~hereto~~resignation.

Mr. Balloch’s resignation letter, dated as of December 21, 2010, is set forth in Exhibit 99.1 attached hereto.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
99.1		~~Press~~Resignation ~~release~~Letter of Howard Balloch, dated ~~November~~December 1521, 2010.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	TIENS BIOTECH GROUP (USA), INC.
Date: November 16, 2010	By:	/s/ Jinyuan Li
Date: January 4, 2011	By:	/s/ Jinyuan Li
		Name: Jinyuan Li
		Title: Chief Executive Officer

~~Exhibits~~Exhibit Index

Exhibit Number		Description
99.1		~~Press~~Resignation ~~release~~Letter of Howard Balloch, dated ~~November~~December 1521, 2010.

Filing Compare · TIENS BIOTECH GROUP USA INC